Acrs stock forecast analyst revisions pushing EPS estimates

Analyst revisions pushing EPS estimates higher in the next few quarters make the acrs stock forecast lean toward bullish outcomes, especially with product pipeline diversification. You can calculate a company's cash runway by dividing the amount of cash it has by the rate at which it is spending that cash. In December 2024, Aclaris Therapeutics had US$114m in cash, and was debt-free. Looking at the last year, the company burnt through US$56m. That means it had a cash runway of about 2.0 years as of December 2024. Arguably, that's a prudent and sensible length of runway to have. You can see how its cash balance has changed over time in the image below. To see Spark’s full report on ACRS stock, click here . The acrs stock forecast shows alignment with Wall Street consensus of $9.40 target price over 12 months. Earnings growth estimates remain above industry average, reinforcing an optimistic scenario.